Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). Results from a first-in-human phase I study of ...
Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor ...
Zanubrutinib showed superior PFS and OS compared to acalabrutinib in R/R MCL, with HRs of 0.57 and 0.43, respectively. The STC approach was used due to the lack of head-to-head trials, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback